N@N

Tiago Fauth Initiated (BMRN) at Buy and Held Target at $120 on, Jun 14th, 2023

Tiago Fauth of Credit Suisse, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Buy and Held Target at $120 on, Jun 14th, 2023.

Tiago has made no other calls on BMRN in the last 4 months.

There are 12 other peers that have a rating on BMRN. Out of the 12 peers that are also analyzing BMRN, 6 agree with Tiago's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Andreas Argyrides of "Wedbush" Maintained at Hold with Decreased Target to $69 on, Thursday, April 27th, 2023
• David Lebowitz of "Citigroup" Maintained at Hold with Decreased Target to $103 on, Thursday, April 27th, 2023
• Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Thursday, April 27th, 2023
• Kostas Biliouris of "BMO Capital" Maintained at Hold with Decreased Target to $102 on, Tuesday, March 7th, 2023
• Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $112 on, Tuesday, February 28th, 2023
• Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023

These are the ratings of the 6 analyists that currently disagree with Tiago

---

• Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $125 on, Thursday, April 27th, 2023
• Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Decreased Target to $120 on, Thursday, April 27th, 2023
• Joel Beatty of "Baird" Maintained at Buy with Increased Target to $127 on, Thursday, April 27th, 2023
• William Pickering of "Bernstein" Initiated at Sell and Held Target at $81 on, Tuesday, March 21st, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $131 on, Tuesday, February 28th, 2023
• Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $118 on, Tuesday, February 28th, 2023

Contributing Sources

---